Mines D`or Orbec Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 375
- Market Cap
- $121.4M
- Website
- http://www.bluebirdbio.com
- Introduction
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Clinical Trials
45
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (38 trials with phase data)• Click on a phase to view related trials
A Study of Participants With β-Thalassemia Treated With Betibeglogene Autotemcel
- Conditions
- Beta-Thalassemia
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 150
- Registration Number
- NCT06271512
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸UCSF Benioff Children's Hospitals, Oakland, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
- Conditions
- Cerebral Adrenoleukodystrophy (CALD)
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 120
- Registration Number
- NCT06224413
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 85
- Registration Number
- NCT04628585
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 35
- Registration Number
- NCT04293185
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Children's National Hospital, Washington, District of Columbia, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
- Conditions
- Cerebral Adrenoleukodystrophy (CALD)
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 35
- Registration Number
- NCT03852498
- Locations
- 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸Boston Children's Hospital/Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- 3
- Next
News
FDA Restricts Bluebird Bio's Skysona Gene Therapy Following Tripled Cancer Risk
The FDA has restricted Skysona gene therapy to cerebral adrenoleukodystrophy patients without alternative treatments after hematologic malignancy rates tripled to 15%.
CMS Launches Multi-State Payment Model to Expand Access to Sickle Cell Gene Therapies
The Centers for Medicare & Medicaid Services unveiled a new outcomes-based payment model with 33 states to expand Medicaid access to gene therapies for sickle cell disease.
bluebird bio Strengthens Leadership Team with Three Key Executive Appointments
bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.
National Resilience Winds Down Six Manufacturing Facilities Despite $2.25 Billion in Total Funding
National Resilience announced plans to wind down six manufacturing facilities across California, Massachusetts, and Florida, citing that capacity expansion has outpaced industry demand.
Carlyle and SK Capital Complete $3-5 Per Share Acquisition of Gene Therapy Pioneer bluebird bio
Carlyle and SK Capital Partners successfully acquired 59.8% of bluebird bio shares through a tender offer that expired May 29, 2025, meeting all conditions for the acquisition.
CRISPR Therapeutics' Casgevy Shows Commercial Progress as Gene Therapy Pipeline Advances
CRISPR Therapeutics and Vertex report encouraging progress with Casgevy, their approved gene therapy for sickle cell disease and beta-thalassemia, with 65 treatment centers now activated globally.
Pfizer Withdraws Sickle Cell Drug Oxbryta Globally Following Safety Concerns
Pfizer has voluntarily withdrawn its sickle cell disease therapy Oxbryta (voxelotor) from all global markets after discovering an imbalance in deaths during clinical trials.
New York Man Becomes First in State to Be Cured of Sickle Cell Disease with Lyfgenia Gene Therapy
21-year-old Sebastien Beauzile has been successfully treated for sickle cell disease at Cohen Children's Medical Center using Bluebird Bio's Lyfgenia gene therapy, becoming the first New Yorker to receive this breakthrough treatment.
Bristol Myers Squibb Acquires 2seventy bio for $286 Million to Gain Full Control of CAR-T Therapy Abecma
Bristol Myers Squibb has agreed to acquire 2seventy bio for $286 million, ending the profit-sharing arrangement for the BCMA-targeted CAR-T therapy Abecma used in multiple myeloma treatment.
Bristol Myers Squibb Acquires 2seventy Bio for $102 Million as Gene Therapy Sector Faces Valuation Challenges
Bristol Myers Squibb has acquired 2seventy Bio for $102 million net, just weeks after Bluebird Bio, 2seventy's parent company, was sold for a mere $30 million, highlighting significant valuation challenges in the gene therapy sector.